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mg daily, was also instituted, with conversion to alternate-day therapy
after the first month. After 6 months of treatment, the patient's
creatinine clearance had risen to 65 mI/mm, and the urinalysis showed
minimal hematuria. A second renal biopsy revealed resolution of active
glomerular lesions; 50% of the glomeruli, however, displayed evidence
of sclerosis and fibrous crescents.
Over the subsequent 5 months, the prednisone dosage was tapered
from 15 mg to 2.5 mg every other day. Left-sided otitis media and
mastoiditis developed and responded only partially to antibiotics.
Malaise, low-grade fever, rhinitis, epistaxis, leg hypesthesia, right foot-
drop, and nephritic urinary sediment ensued over the subsequent
month. Sinus radiographs were negative, but a plain chest x-ray showed
a 3 cm retrocardiac mass, which was excised by thoracotomy. Histolog-
ic examination revealed granulomatous lesions with necrosis (Fig. IB)
as well as a chronic vasculitis (Fig. 1C) typical of Wegener's granuloma-
tosis. Institution of daily prednisone and oral cyclophosphamide thera-
py produced complete resolution of systemic and respiratory tract
symptoms. Improvement in peripheral neuropathy and resolution of
urinary sediment abnormalities occurred. Renal function has remained
________________________________________________________________
stable, with a creatinine clearance of 68 mI/mm; the remission has been
maintained for more than one year.
Case presentation Discussion
A 54-year-old white woman was referred for evaluation of edema.
Over the preceding 3 months, she had noted myalgias in her legs and
dysesthesia of both feet, but no arthritis was present. An otorhinolaryn-
gologist was consulted because she complained of a bad taste in her
mouth. She denied rhinorrhea, epistaxis, earache, hearing difficulties,
and lower respiratory symptoms. No ear, nose, or throat pathology was
found on physical examination; radiographs of the sinuses and chest
were normal. The patient was hospitalized for further evaluation of the
edema and peripheral neuropathy.
Laboratory examination revealed: hematocrit, 32%; serum creati-
nine, 2.7 mg/dl; creatinine clearance, 22 mllmin; and urine protein, 0.9 g
per day. Urinalysis disclosed proteinuria and hematuria, and the
urinary sediment was replete with red blood cell and white blood cell
casts. A streptozyme test, syphilis serology, and tests for hepatitis-B
surface antigen, cryoglobulins, and antinuclear and anti-DNA antibod-
ies were negative; the C3 complement concentration was normal.
During evaluation in the hospital, she developed bilateral auricular
pain, erythema, and swelling. Biopsy of the ear was not performed, but
the chondritis promptly responded to administration of topical steroids.
An open renal biopsy showed cellular crescents in more than 70% of
glomeruli, and extensive segmental necrosis in the tufts (Fig. IA). No
vasculitic lesions or granulomas were found. Trivial mesangial deposits
were reported on immunofluorescence and electron microscopy.
The patient was transferred to the National Institutes of Health for
treatment of crescentic glomerulonephritis under an investigational
protocol. Methylprednisolone, 1.0 g/m2 daily for 5 days, was initiated,
followed by 6 additional, single monthly infusions. Oral prednisone, 60
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DR. JAMES E. BALOW (Chief, Clinical Nephrology Service,
National Institute of Arthritis, Diabetes, and Digestive and
Kidney Diseases, National Institutes of Health, Bethesda,
Maryland): This patient illustrates a most intriguing constella-
tion of clinical features. There was a strong suspicion of a
systemic disease because of the presence of nearly incapacitat-
ing malaise, myalgias, and dysesthesias. Dysgeusia was a
troublesome symptom, but no adequate explanation was appar-
ent. Indeed, objective signs were meager except for glomerulo-
nephritis and auricular chondritis. The chondritis and focal
necrotizing glomerulonephritis with crescents led the referring
physicians to suggest the diagnosis of rapidly progressive
glomerulonephritis (RPGN) associated with relapsing poly-
chondritis [1, 2].
Relapsing polychondritis, typically a progressive condition,
is defined by the presence of three or more of the criteria in
Table 1. Approximately 70% of cases are considered "pri-
mary," whereas 30% are associated with rheumatoid arthritis,
Sjogren's syndrome, systemic lupus erythematosus, or system-
ic vasculitis. Antibodies to type-Il collagen have been observed
in some patients. Several cases of rapidly progressive and
crescentic glomerulonephritis have been reported in relapsing
polychondritis [3, 4]. But the diagnosis of relapsing polychon-
dritis was not made in the patient under discussion here because
of the lack of sufficient criteria.
Other diagnostic entities also were considered. The nonspe-
cific but imposing clinical symptoms complicated by rapid-
ly progressive and crescentic glomerulonephritis raised the
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Fig. 1. Kidney and lung biopsies. A Glomerular lesion showing segmen-
tal proliferation, necrosis, and crescent formation (x250). B Multinucle-
ated giant cells in the border between a necrotic area and granuloma-
tous tissue of the lung (x220). C Vasculitis of a medium-sized pulmo-
nary vessel (x80).
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Table 1. Relapsing polychondritis
1. Recurrent auricular chondritis
2. Non-erosive polyarthritis
3. Nasal chondritis
4. Ocular inflammation: conjunctiva, cornea, sclera, and/or uveal
tract
5. Chondritis of respiratory tract
6. Auditory and/or vestibular damage
Criteria adapted from Ref. 1.
question of systemic vasculitis, but objective criteria for this
diagnosis were also lacking. By a process of exclusion, the
clinicians caring for the patient were left with a presumptive
diagnosis of type-Ill RPGN or no-immune-deposit, crescentic
glomerulonephritis. Because a substantial proportion of pa-
tients with type-Ill RPGN have vague and ill-defined constitu-
tional symptoms [5—101, some clinicians have entertained the
possibility that a certain proportion of these patients in fact
might have systemic vasculitis. These considerations clearly
are relevant to the current patient. Nonetheless, the favorable
clinical response, with marked improvement in renal function
following treatment with intermittent pulses of methylpredniso-
lone and oral prednisone, introduced a further delay before the
ultimate diagnosis was made. The subsequent emergence of a
clinical vasculitic syndrome, with the typical granulomatous
inflammation of the upper and lower respiratory tract, histolog-
ic evidence of vasculitis, and flare of glomerulonephritis, estab-
lished the diagnosis of Wegener's granulomatosis when the
patient's condition worsened during steroid tapering. Assuming
that her initial illness was also due to Wegener's granulomato-
sis, albeit manifested in a more subtle way, it may be surprising
that she had responded so dramatically to corticosteroids. On
the other hand, it is notable that a complete and sustained
remission was induced by cyclophosphamide therapy.
Vasculitis and necrotizing glomerulonephritis
Vasculitic diseases usually are encountered by nephrologists
in one of the following contexts. A renal disorder can be a
component of a well-defined vasculitic syndrome, but the
diagnosis of renal vasculitis is often evasive because of nonspe-
cific clinical features and/or a paucity of pathologic changes. On
the other hand, certain histologic features on renal biopsy can
suggest a vasculitic process and should prompt a search for
additional clinical evidence of systemic disease. To be sure, no
glomerular lesion is pathognomonic of vasculitis, and support-
ing evidence of extraglomerular vasculitis often is elusive, even
in cases of clear-cut, autopsy-proved renal vasculitis [11—14].
Nonetheless, the presence of focal segmental necrotizing gb-
merulonephritis, with minimal endocapillary proliferation and
basement membrane abnormalities, and insignificant deposits
of immune reactants, are taken to indicate systemic vasculitis.
Indeed, as shown in Table 2, the differential diagnosis of focal
segmental necrotizing gbomerulonephritis is dominated by vas-
culitic causes, Classic polyarteritis nodosa is absent from the
list because it is, by definition, vasculitis of medium-sized
vessels. Fibrinoid necrosis in glomeruli occurs more commonly
in no-immune-deposit (type-Ill) RPGN than in anti-GBM (type-
I) or in immune-complex—associated (type-Il) RPGN. Yet all
three forms of RPGN feature some clinical or pathologic
evidence of vasculitis [5—10, 15, 161. The relationship of type-Ill
I.
Table 2. Differential diagnosis of focal segmental necrotizing
glomerulonephritis
1. Polyarteritis nodosa group of systemic vasculitis
Microscopic polyarteritis nodosa
Allergic granulomatosis
Overlap syndrome
2. Wegener's granulomatosis
3. Rapidly progressive (crescentic) glomerulonephritis
4. Lupus nephritis
5. Henoch-Schönlein and IgA nephropathy
6. Nephritis of bacterial endocarditis
Table 3. General classification of systemic vasculitides
Polyarteritis nodosa group of systemic vasculitis
Classic polyarteritis nodosa
Microscopic polyarteritis nodosa
Overlap syndrome
2. Cutaneous (hypersensitivity) vasculitis
3. Allergic granulomatosis
4. Wegener's granulomatosis
5. Lymphomatoid granulomatosis
6. Giant cell arteritis
Temporal/cranial arteritis
Takayasu's disease
7. Vasculitis of systemic diseases
Systemic lupus erythematosus
Henoch-Schönlein purpura
Systemic sclerosis
Cryoglobulinemia
8. Non-immune-deposit RPGN
a Relationship to vasculitic disease suspected but not proved.
RPGN to systemic vasculitis, already emphasized by several
authors, was highlighted recently by Serra and colleagues at
Guy's Hospital [141. Upon reexamining certain patients previ-
ously described as having idiopathic crescentic and necrotizing
glomerulonephritis [7], these authors concluded that adequate
clinical evidence indicated that some of these patients actually
had renal vasculitis.
Classification of systemic vasculitis
Vasculitis is a general, descriptive term, analogous to glomer-
ulonephritis in both a clinical and pathologic sense. Classifica-
tion of the systemic vasculitides is a major problem, among
other reasons because the causes and pathogeneses of these
diseases are obscure. As Spargo, Seymour, and Ordenez note:
"The nomenclature and classification of vasculitides is an
etymobogic quagmire: few who enter the area emerge un-
scathed" [17]. Indeed, a wholly satisfactory classification of
systemic vasculitis does not exist. The scheme proposed in
Table 3 specifies a number of vasculitides for which specific
criteria are widely accepted. Cutaneous vasculitis, allergic
granulomatosis, Wegener' s granulomatosis, lymphomatoid
granulomatosis, and giant cell arteritis are discrete entities,
although most are quite uncommon [18—21]. The category
labeled polyarteritis nodosa (PAN) group of systemic vasculitis,
on the other hand, covers a broad spectrum of disease. Polyar-
teritis nodosa, in the narrow context originally described by
Kussmaul and Maier in the middle of the 19th century, is
relatively rare [221. They described the syndrome as comprising
nodular swelling of arteries with Bright's disease and progres-
sive muscle weakness. Whether this form of polyarteritis no-
dosa should be considered pathogenetically distinct because of
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Reported series Number Any
Unselected
Frohnert [23]
Lieb [24]
Cohen [25]
Scott [26]
Renal
130
64
53
80
76
64
66
76
28
34
26
48
Serra [14]
Ronco [27]
53
43
100
"Most"
85
40
the extreme nature of its vascular disease, or whether it is
simply the advanced stage of any form of inadequately con-
trolled arteritis of medium-sized vessels, has not been ascer-
tained. At present, however, classic polyarteritis nodosa is
viewed as encompassing necrotizing vasculitis of medium-sized
arteries with or without the appearance of aneurysm formation.
"Microscopic polyarteritis nodosa" sometimes has been
used interchangeably with "hypersensitivity vasculitis." But
clinicians and pathologists tend now to apply the term hyper-
sensitivity vasculitis to cutaneous vasculitis [12], in which an
allergic process is more commonly found. Microscopic polyar-
teritis nodosa is preferably reserved for specifying small-vessel
vasculitis (mainly arterioles and capillaries) of major visceral
organs.
Not uncommonly, the level of the vasculature involved in
patients with systemic vasculitis includes both small- and
medium-sized vessels. This has prompted the use of the term
"overlap syndrome of systemic vasculitis" [18, 19]. Some
investigators prefer to use the simple, unmodified term "polyar-
teritis nodosa" rather than overlap syndrome to describe such
patients. Although exceptions are recognized, identification of
a specific offending stimulus is rare in any of the PAN group of
systemic vasculitis.
Understanding systemic vasculitis is made even more diffi-
cult by the variable description given to these entities by
different medical subspecialists. These variable descriptions
reflect the skewed patient populations encountered. Patients
with distinct constellations of clinical signs and syndromes of
vasculitis consult rheumatologists, dermatologists, neurolo-
gists, and gastroenterologists. Such patients can be quite differ-
ent from those usually encountered by nephrologists. As Table
4 shows, the prevalence of renal involvement ranged between
64% and 76% in patients with polyarteritis nodosa in unselected
series [23—26]; the prevalence was 100% in patients reported by
nephrologists [14, 27]. More striking is the range in prevalence
of azotemia. These figures emphasize that clinical differences
must be scrutinized when one analyzes different series of
patients with vasculitis.
Patho genesis of systemic vasculitis
Although systemic vasculitis is presumed to have an immuno-
logic basis, a paucity of data is available to corroborate this
presumption. Immunologic features are equally obscure in
classic and microscopic polyarteritis nodosa. The role of circu-
lating immune complexes is controversial; complexes are com-
monly present during flares of vasculitis [19, 24, 27] but rarely
are demonstrable in tissue sites of disease activity [11, 12, 17,
27]. Complexes, when present in the circulation, often are
cryoprecipitable and contain rheumatoid factor activity. Im-
mune-complex—mediated vasculitis can be induced by exoge-
nous antigens in early phases of serum sickness, but no good
models of sustained immune-complex vasculitis have been
developed [12]. The strongest candidate for human immune-
complex vasculitis is hepatitis B surface antigen, which ranges
in prevalence from 6% to 41% in reported series of systemic
vasculitis [24, 25, 28—30]. However, its pathogenetic role re-
mains in doubt because persistent antigenemia is not associated
with consistent disease expression and can occur in the various
types of vasculitis. The role of defective reticuloendothelial
clearance in systemic vasculitis is intriguing but obscure [311.
By inference from the histology of the vasculitic inflammatory
lesions, cell-mediated immune mechanisms could be operant,
but direct proof of this hypothesis is lacking in any form of
systemic vasculitis.
Clinical features of systemic vasculitis
Several reviews have described the clinical and pathologic
features of the different systemic vasculitides [18—21, 32—35]. I
will limit the remainder of this discussion to the clinical,
diagnostic, and therapeutic aspects of polyarteritis nodosa
(both the classic and microscopic forms), Wegener's granulo-
matosis, and Henoch-Schönlein disease.
Polyarteritis nodosa. Diagnosis of classic polyarteritis no-
dosa is based on the recognition of a vasculitic syndrome with
supportive evidence deriving from radiologic or pathologic
studies or both. The vasculitic syndrome comprises a variable
mix of fever, weight loss, anemia, arthritis, dermatitis, myopa-
thy, neuropathy, and gastrointestinal and renal disease. In the
medium-sized-vessel disease of classic polyarteritis nodosa,
renal involvement is expressed by low-grade urinary sediment
activity, proteinuria, and evolving azotemia secondary to isch-
emia or renal infarction. Necrotizing and/or crescentic glomeru-
lar disease is rare and, if present, would prompt many to use the
designation overlap syndrome. Renin-mediated hypertension is
common in classic polyarteritis nodosa. Major visceral beds
display vascular lesions in multiple stages, from fibrinoid necro-
sis and acute thrombosis to widespread fibrosis; uneven healing
with aneurysm formation and disruption of the elastic lamina is
common. Biopsy of an organ with clinical or laboratory evi-
dence of dysfunction is ideal for verifying the diagnosis of
vasculitis. However, in the absence of localized clinical abnor-
malities or conclusive biopsy results, one should consider
angiography. As a blind procedure, angiography is preferable to
tissue sampling of an asymptomatic site. Travers et al reviewed
17 cases of polyarteritis nodosa and reported that hepatic,
renal, and mesenteric arteriography yielded comparable diag-
nostic information and assisted in the diagnosis of 13 of the 17
patients [36].
A vasculitic syndrome with constitutional features similar to
those in the classic form may presage the diagnosis of micro-
scopic polyarteritis nodosa. Hypertension is relatively rare, and
major ischemic vascular complications are unexpected unless a
true overlap condition exists. Glomerulonephritis and azotemia
usually are present. The glomerular vasculitic lesion, as indicat-
ed previously, typically produces focal segmental necrosis and!
or extensive cellular crescents (Fig. 2A). Immune deposits
Table 4. Prevalence of renal disease in polyarteritis nodosa
Renal abnormality (%)
Azotemia
a Numeral in bracket denotes reference number.
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Fig. 2. Microscopic po/yarteritis of the kidney. A Glomerular lesion exhibiting several stages of injury including proliferation, necrosis, crescent
formation, and an acellular nodule of sclerosis (x330). B Renal vessels showing scant mononuclear cells in the wall of an arteriole and cuffing
around a venule (x220).
observed by fluorescence or electron microscopy are sparse or
absent. Diligent search of tissue blocks of the biopsy specimens
is often necessary to locate extraglomerular small-vessel vascu-
litis to support the diagnosis of microscopic polyarteritis nodosa
(Fig. 2B). The paucity and unevenness of histologic vasculitis
has prompted some to advocate open renal biopsy to obtain
large tissue samples when diagnosis of microscopic polyarteritis
nodosa is suspected. Aneurysms would be exceptional but
vasculitis in mid-sized vessels is often present and frequently
gives rise to symptoms in extrarenal tissues [13].
A typical course of polyarteritis nodosa is difficult to describe
because of the highly variable systemic involvement. The broad
range of natural history in this condition has been described in
several excellent reviews previously cited. In general, approxi-
mately 50% of patients follow a low-grade, remitting-relapsing
course. But vasculitis involving major viscera can be aggressive
and associated with substantial risk of mortality. Deaths direct-
ly related to active vasculitis occur primarily within the first few
months, whereas late deaths are more often due to chronic
vascular compromise and to complications of prolonged or
excessive treatment with immunosuppressive drugs [18].
Differences in outcome would be anticipated between classic
and microscopic polyarteritis nodosa. Indeed, the cause of
death reported in published series reflects some of these
differences. As Table 5 illustrates, the overall mortality in two
unselected series dominated by classic polyarteritis nodosa was
Table S. Causes of death in polyarteritis nodosa
Cause of deathc
Percentage of patients
study
dying during
Unselected seriesa
(n = 117)
Renal seriesb
(n = 53)
Renal failured
Extrarenal vasculitis
Infection
Otherc
Unknown
9
50
6
30
6
51
11
3
17
17
Unselected series derived from data of Lieb [241 and Cohen 125].
Patients primarily with classic polyarteritis nodosa and overlap syn-
drome. Overall mortality was 54/117 or 46% of patients.
h Renal series of Serra [14]. Patients primarily with microscopic
polyarteritis nodosa. Overall mortality was 35/53 or 66% of patients.
Death was usually from multiple factors; primary cause listed.
d Mortality rate of all published series affected by restricted use of
renal replacement therapy during part of study period.
Mostly cardiac and cerebrovascular disease or malignancy.
46% [24, 25], whereas that in the series principally comprising
patients with microscopic renal vasculitis was 66% [14]. Death
was mainly due to active extrarenal vasculitis in the unselected
series, but primarily due to renal failure in the patients with
microscopic polyarteritis nodosa. The dominance of renal com-
plications in the microscopic form of vasculitis is further
loot-' Cytotoxics - 100
Steroids
• Frohnert 1967
• Lieb 1979
• Cohen 1980
• Sack 1975
3 4 5 0
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Table 6. Evolution of renal function in renal vasculitis of microscopic
polyarteritis nodosaa
Renal status
Last follow-up
Number Percentage
End-stage disease (ESRD)b
Death
Transplant
Azotemiac
19
18
1
10
36
34
2
19
a Dataderived from 53 patients reported by Serra [14].
b One additional patient with early ESRD was able to discontinue
hemodialysis after 18 months.
GFR estimated at less than 80 mI/mm.
reflected by the renal status at last follow-up in the series by
Serra Ct al [14], as shown in Table 6. Of the 18 surviving
patients, 10 exhibited significant chronic renal insufficiency.
Treatment of polyarteritis nodosa is controversial, and analy-
sis is complicated by the absence of studies utilizing concurrent
comparisons of different therapies [37]. Figure 3, a synthesis of
published data from unselected series, compares actuarial sur-
vival of untreated patients with that of patients treated with
corticosteroids or cytotoxic drugs. A consensus exists that
corticosteroids have substantially improved the outlook for
patients with polyarteritis nodosa. Controversy exists, howev-
er, as to whether cytotoxic drugs—principally azathioprine or
cyclophosphamide—have even greater efficacy. The series by
Lieb and coworkers favors the use of cytotoxic drugs [241; that
of Cohen et al shows an overall result comparable to that with
corticosteroids [25]. Fauci and colleagues have provided addi-
tional support for the use of cyclophosphamide in the PAN
group of systemic vasculitis [35]. These investigators have
stressed the efficacy of cyclophosphamide in patients respond-
ing poorly or incompletely to corticosteroids, but also have
emphasized cyclophosphamide's effectiveness in reducing long-
term steroid toxicity. Reversion of aneurysms following cyclo-
phosphamide therapy has been documented [38].
Comparable data are lacking for treatment of the microscopic
form of polyarteritis nodosa [14]. However, the approach to
treatment is generally comparable to that of classic polyarteritis
nodosa. There appears to be a somewhat greater reliance on
pulse methyiprednisolone, cyclophosphamide, and/or plasma
exchange therapy, a practice that is patterned after the ap-
proach commonly employed in rapidly progressive glomerulo-
nephritis. The systemic manifestations of microscopic polyar-
teritis nodosa often respond dramatically to conventional thera-
py with corticosteroids, cyclophosphamide, or both.
To summarize, corticosteroids are the mainstay of therapy
for the PAN group of systemic vasculitis. The duration and
amount of their use should be as short and as low as possible to
control disease activity and to minimize insidious long-term
toxicity. Although azathioprine may be considered, we prefer
to use cyclophosphamide for: (1) inadequate response to corti-
costeroids; (2) unusually aggressive, progressive, or persistent
disease; (3) involvement of viscera with a low tolerance to a
vascular insult (that is, cardiac, renal, central nervous system,
gastrointestinal); (4) dependency on a high dosage of steroids
for more than two months; or (5) accelerated steroid complica-
tions. Few data are available upon which one can assess the
efficacy of intermittent pulse therapy with methyiprednisolone
Fig. 3. Effect of treatment on cumulative survival of patients with
polyarteritis nodosa. Curves were constructed from data in series
indicated. Shaded areas represent the range in survival in untreated
patients and in those treated with steroids. Separate curves are shown
for the two series reporting the effects of cytotoxic agents. (From Ref.
37.)
or cyclophosphamide or of plasma exchange, all of which are
being investigated for treatment of polyartentis nodosa.
Wegener's granulomatosis. Generally speaking, the diagno-
sis of Wegener's granulomatosis is relatively straightforward.
The patient discussed today is an exception. Wegener's granu-
lomatosis is characterized by chronic inflammation, granulo-
mas, and vasculitis of the upper and lower respiratory tract, as
well as by glomerulonephritis [39—41]. Variable distribution of
vasculitis in other organs is expected. The renal disease typical-
ly begins as focal segmental necrotizing glomerulonephritis,
which rapidly can progress to severe crescentic glomerulone-
phritis. As in vasculitis of the polyarteritis nodosa type, im-
mune-compex deposits are rarely seen by fluorescence or
electron microscopy of renal biopsy material [12, 27, 40—421.
Overall, the risk of end-stage renal failure within 10 years of
diagnosis of Wegener' s granulomatosis is approximately 10% in
patients with any evidence of glomerulonephritis, 33% in pa-
tients with nephritis and azotemia before treatment is begun,
and approximately 50% in those with rapidly progressive gb-
merulonephritis [28, 43]. Figure 4 illustrates the actuarial sur-
vival of 44 patients with renal disease at the time of diagnosis of
Wegener's granulomatosis who were studied at the NIH. The
risk of death or renal failure was 17% at 5 years and 33% at 10
years. Patients with rapidly progressive glomerulonephritis and!
or at least 2.5 g/day of proteinuria before treatment had a
considerably higher risk of renal failure within the first 3 years.
A virtual consensus has emerged regarding the treatment of
Wegener's granulomatosis because of the dramatic improvement
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Fig. 4. Cumulative survival in patients with Wegener's granulomatosis.
Fhe curves represent the probability of escaping renal failure or death at
various intervals of follow-up. Also shown is the expected course of
patients with 2.5 glday of proteinuria or rapidly progressive glomeru-
onephritis (RPGN) before cytotoxic drug therapy was initiated. (From
Ref. 37.)
in the prognosis of the disease since the advent of cytotoxic
drug therapy [19, 37, 39—411. Survival at one year, historically
20% when only supportive care was available [44], improved
marginally to approximately 34% with the use of corticosteroids
[45, 46]. With the addition of cyclophosphamide therapy, the
one-year expected survival increased to over 80% [39, 47], and
in the NIH series it has risen to 95% (Fig. 4).
Guidelines for the use of cyclophosphamide in Wegener's
granulomatosis have been widely publicized in the references
previously cited. In my estimation, the most pressing issue that
remains relates to the need for new approaches for maintenance
immunosuppressive therapy. Using conventional daily cyclo-
phosphamide therapy for prolonged periods is far from ideal
because of chronic bone-marrow suppression, the low but real
risk of severe hemorrhagic cystitis, bladder fibrosis, and lym-
phoreticular malignancy [481.
Henoch-SchOnlein disease. The vasculitis of Henoch-SchOn-
lein purpura is often accompanied by clinical features akin to
those of polyarteritis nodosa [18, 19, 49]. Skin, joint, gastroin-
testinal, and renal involvement characterize Henoch-Schönlein
disease. A distinctive feature of this disease, however, is the
presence of immune complexes—particularly containing IgA—.-
in the dermal and glomerular lesions [50—52]. The presence of
mesangial and subendothelial immune deposits suggests that
the renal lesion of Henoch-Schönlein disease is more closely
related to lupus nephritis than to the nephritis encountered in
the other forms of systemic vasculitis.
The usual course of Henoch-Schonlein disease, even when
glomerulonephritis is present, is transient and self-limited.
Complete recovery generally occurs within a few weeks. The
A. Microscopic0 hematuria
Fig. 6. Prognosis of patients with Henoch-SchOnlein nephritis accord-
ing to renal pathologic features. Results are based on composite data
on 193 patients from three separate published reports [53, 54, 56].
(From Ref. 37.)
extent of glomerular disease is usually the most important
determinant of the long-term prognosis in the subset of patients
with chronic persistent or relapsing disease. Figure 5 represents
the renal outcome data compiled from four reported series of
more than 200 patients with Henoch-Schönlein nephritis [53—
56]. The risk of progressive renal insufficiency was significantly
increased only in patients with glomerulonephritis complicated
by hypertension, azotemia, oliguria, and/or hypoproteinemia
(designated as complicated nephrotic syndrome, D). Figure 6
summarizes additional data from three of the four reports I have
already cited [53, 54, 56]. As shown, less than 50% glomerular
crescents did not affect renal outcome within an observation
period of approximately 3 years, whereas a higher percentage of
cellular crescents was associated with a more adverse
prognosis.
Optimal treatment of progressive Henoch-Sôhönlein nephri-
tis is controversial [37, 49]. Consensus exists that conventional
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corticosteroid therapy alone is not often efficacious in this
disease. Cyclophosphamide has been relied upon most often for
treatment of severe glomerular disease. Plasmapheresis therapy
may warrant further study in certain cases of refractory or
progressive Henoch-Schönlein nephritis [57].
Epilogue
Nihilists who have attempted to integrate the literature on
systemic vasculitides may conclude that there has been little
refinement in knowledge since Sir William Osler lumped many
of the diseases in the current classification system into an
erythema group of skin diseases with systemic complications.
Admittedly, progress in clarifying the pathogenesis of the
systemic vasculitides has been meager. But new treatment
strategies have reduced mortality and morbidity stemming from
several of the systemic vasculitides themselves as well as from
the overzealous or injudicious use of immunosuppressive
therapy.
Questions and answers
DR. NICOLAOS E. MADIAS: I gather from your presentation
that the pathogenesis of systemic vasculitides remains quite a
mystery. Could you expand on the possible role of cell-
mediated immune mechanisms in the pathogenesis of these
disorders?
DR. BALOW: Cell-mediated immune mechanisms have been
implicated but there are few substantiating data on this point.
Clarification of this issue is hampered by lack of a good
experimental model of chronic vasculitis and by the difficulty of
proving this point in human subjects. Certain inferences derived
from clinical and pathologic features of systemic vasculitis
provide indirect support for this hypothesis. These diseases
have general characteristics akin to those of a number of
hypersensitivity conditions and they respond to immunosup-
pressive drugs. Morphologically, cell-mediated mechanisms are
inferred by the paucity or absence of humoral constituents in
vasculitic sites; rather, the vasculitic lesions are dominated by
mononuclear cell infiltrates, including occasional granulomas.
Unfortunately, none of these arguments provides a definitive
insight into the importance of cell-mediated immune mecha-
nisms in the pathogenesis of systemic vasculitides.
DR. JEROME P. KASSIRER: Given that our current therapeutic
choices are so limited, in your opinion how critical is it that we
know the precise histologic subclassification among the vasculi-
tides? Assuming that one is not engaged in a research project to
identify differences in therapeutic responses among the sub-
types, would it be legitimate simply to treat with steroids, or
perhaps steroids and cyclophosphamide, and not bother to
distinguish the type?
DR. BALOW: Even though there is considerable overlap in the
therapeutic approach to a number of the vasculitic diseases, I
have little doubt that the physician's ability to instruct and to
treat the patient is facilitated by refining the diagnosis. Compli-
cations can be better anticipated. Therapeutic approaches are
evolving in several of the vasculitic diseases. The differences
may be subtle but also important. For example, restrained use
of immunosuppression is appropriate in most cases of hyper-
sensitivity vasculitis or Henoch-Schönlein disease, whereas
cytotoxic drugs are administered early in Wegener's granulo-
matosis. In the PAN group of systemic vasculitis, I believe the
critical therapeutic issue relates to the relative efficacy early in
the disease of steroids alone compared to steroids and cyclo-
phosphamide; or in the case of microscopic polyarteritis with
severe glomerulonephritis, we need to know more about the
appropriate role of pulse steroids and plasma exchange. Until
these questions are better defined, I would hope that clinicians
will be compelled to enter patients into studies in which these
diagnostic and therapeutic issues can be further analyzed.
DR. KASSIRER: How does azathioprine compare to other
cytotoxic drugs with respect to its efficacy in vasculitis?
DR. BALOW: There are no concurrent comparisons of the
efficacy of different agents in the vasculitic diseases discussed
today. Authors of the published reports supporting cytotoxic
drugs over steroids in the treatment of polyarteritis nodosa
utilized azathioprine in the majority of patients [24]. I have been
impressed with the number of patients who have been inade-
quately responsive and poorly controlled with azathioprine but
whose disease seems to remit better with cyclophosphamide.
This view is shared by Dr. Fauci at NIH who prefers to use
azathioprine for patients intolerant to or having complications
from cyclophosphamide, particularly as maintenance therapy
after remission of systemic vasculitis or Wegener's granuloma-
tosis has been induced, Were toxicity not an issue, it is my
feeling that few experienced investigators would give priority to
azathioprine. I am hopeful that the experience we have gained
with intermittent cyclophosphamide treatment in SLE showing
significant efficacy but reduced toxicity over conventional
cyclophosphamide therapy can be brought to bear on the
management of other renal vasculitides.
DR. DAVID CAHAN (Chi ef of Nephrology, Faulkner Hospital,
Boston): What is the desirability of using alternate-day steroid
therapy in these patients?
DR. BALOW: I am a strong advocate of switching most
patients to alternate-day therapy as soon as possible. In general
we don't begin switching to an alternate-day schedule for 4 to 8
weeks, depending on the status of the patient. We are generally
slow to reduce the dose below approximately 15 mg of predni-
sone every other day (in an average-sized adult) until the
disease has been in remission for several months. Admittedly,
this is empiric clinical practice because there is a paucity of
objective measures of disease activity, especially in polyarteri-
tis nodosa.
The patient who appears to depend on daily steroids for long
periods of time presents a special problem. It is my opinion that
the threat of insidious steroid complications should continuous-
ly influence management decisions. Although good comparison
studies of the rates of complications of daily versus alternate-
day steroids have not been done, there is broad consensus that
alternate-day therapy is associated with a reduced prevalence
of severe cushingoid features, hypertension, osteonecrosis, and
possibly cataracts. Whether further reduction of steroid compli-
cations can be achieved by even less frequent than alternate-
day maintenance therapy or by the use of intermittent steroid
pulse therapy remains to be determined.
DR. MADIAS: Have you employed repeat morphologic exami-
nation of the kidney as a measure of efficacy in the treatment of
systemic vasculitides?
DR. BALOW: We don't have biopsy information collected in a
prospective fashion comparable to our studies in SLE. Subtle
morphologic changes may be less relevant in the systemic
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vasculitides; most of these diseases tend to exhibit bursts of
renal activity rather than to follow a chronic progressive
course.
DR. RONALD D. PERRONE (Division of Nephrology,
NEMCI-I): You mentioned that you were not able to find a
correlation between vessel aneurysms and organ dysfunction.
Does this indicate that concomitant small-vessel vasculitis must
be present in patients with major organ dysfunction?
Da. BALOW: That may well be true, but it is difficult to prove.
However, vascular insufficiency due to vasculitis of medium-
sized vessels is not always associated with aneurysm formation.
In short, it is unlikely that aneurysms per se are important in the
perfusional disturbances of organs affected by vasculitic pro-
cesses, but rather aneurysms reflect the severity and duration
of the vasculitis.
DR. GEETHA NARAYAN (Division of Nephrology, St. Eliza-
beth's Hospital, Boston): Do you have any data on the effects of
intermittent corticosteroids versus intermittent cyclophospha-
mide in the treatment of crescentic glomerulonephritis?
DR. BALOW: Pulse methylprednisolone therapy has rather
subtlely evolved as the therapy of choice in crescentic glomeru-
lonephritis, including that due to underlying vasculitic diseases.
Formal concurrent comparison of conventional prednisone and
pulse methylprednisolone has not been, and I suspect will not
be, done. We have begun an investigational protocol to com-
pare pulse methylprednisolone with pulse cyclophosphamide in
crescentic glomerulonephritis, but we do not have adequate
data to address your question at this time.
DR. MICHAEL P. MADAIO (Division of Nephrology,
NEMCJ-1): Does intravenous pulse steroid therapy affect cres-
cent formation irrespective of the underlying process, or does it
have a specific effect on selected diseases? Furthermore, is this
effect different from the mechanism of action of conventional
oral prednisone therapy?
DR. BALOW: There are no directly relevant data with which I
can respond to your first question. There is only some sugges-
tion that crescentic glomerulonephritis caused by anti-GBM
antibody is more resistant to any therapy than is that due to
other mechanisms; but this may not necessarily be related to
differential effects of steroids on the crescentic components per
se.
Regarding mechanisms of action of different regimens of
steroids, again, there is only modest information. The pharma-
codynamics of pulse versus oral steroids are obviously differ-
ent. The lymphopenia and depression of cell-mediated immuni-
ty are more profound with pulse therapy, More striking, howev-
er, is that the biologic or clinical effects of corticosteroids often
persist far beyond the pharmacologic and the currently measur-
able immunologic effects. It is known that steroids bind to
cytosolic receptors and are translocated to cell nuclei, where
they subsequently modify cellular functions. This may help to
explain the efficacy of intermittent steroid therapy. Further-
more, it is possible that megadose pulse therapy may reach
types and numbers of receptors not reached by conventional
steroid therapy. These questions need to be addressed if we are
to use steroid therapy optimally.
Da. MADIAS: Could you elaborate on the use of the intrave-
nous, intermittent program of cyclophosphamide therapy?
DR. BALOW: Our motivation for developing novel forms of
administering cyclophosphamide in SLE stemmed mainly from
the following considerations, First, there was evidence that
conventional cyclophosphamide exhibited greater efficacy than
did steroids alone in lupus nephritis. Yet there was reluctance
to endorse cyclophosphamide because of the frequency of toxic
side effects. Intermittent therapy was considered to be an
alternative to maximize efficacy and minimize toxicity. Second,
animal models of autoimmune disease, particularly murine
SLE, responded favorably and in a prolonged fashion to high-
dose pulse cyclophosphamide.
Our largest experience has been with the use of 0.5 to 1.0 gI
m2 of cyclophosphamide given intravenously every 3 months.
Patients with more serious forms of lupus nephritis and those
with idiopathic crescentic glomerulonephritis currently are re-
ceiving monthly infusions of comparable doses of cyclophos-
phamide. Tolerance of intermittent cyclophosphamide therapy
is good. No cases of hemorrhagic cystitis have been observed.
Cumulative bone marrow suppression seen with conventional
cyclophosphamide has been avoided. Preliminary estimates
indicate that gonadal toxicity may be reduced. Unfortunately,
herpes zoster continues to occur at a frequency comparable to
that seen with conventional cyclophosphamide regimens. Major
systemic infections have not been observed, but assiduous care
is undertaken to avoid severe or prolonged leukopenia after
each injection of cyclophosphamide.
DR. MADAIO: In view of the frequent association of rapidly
progressive glomerulonephritis and vasculitis, how intensively
should a diagnosis of vasculitis be pursued early in the course of
the disease?
DR. BALOW: As I alluded to earlier, clinical suspicion of
underlying vasculitis is often raised in patients with minimal
immune-deposit crescentic glomerulonephritis. Serra and col-
leagues from Guy's Hospital in London have underscored this
point by reassigning certain patients with crescentic glomerulo-
nephritis to the group with microscopic polyarteritis nodosa
[14]. It is not clear at this time whether such distinctions are of
practical importance in terms of prognosis or therapeutic re-
sponse, but they should be developed as investigative issues.
DR. PEDRO PONCE (Nephrolo gist, Curry Cabral Hospital,
Lisbon, Portugal): What is the role of plasmapheresis in the
treatment of systemic vasculitides?
DR. BALOW: At the moment, our own approach is to confine
the use of plasmapheresis to patients responding inadequately
to immunosuppressive drugs. I think it is also important to
determine whether plasmapheresis may be effective in the early
induction period in severe systemic vasculitis, before pharma-
cologic agents are optimally active.
Reprint requests to Dr. J. Balow, National Institutes of Health, Bldg.
10, Room 3N112, Bethesda, Maryland 20205, USA
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